<DOC>
	<DOCNO>NCT01250119</DOCNO>
	<brief_summary>This study assess prevalence epidermal growth factor receptor ( EGFR ) mutation newly diagnose patient locally advanced metastatic non-small cell lung cancer ( NSCLC ) . Patients positive EGFR mutation result enter open-label , single arm study evaluate progression-free survival quality life first-line Tarceva ( erlotinib ) therapy . Patients receive Tarceva dose 150 mg orally daily . Anticipated time study treatment progressive disease unacceptable toxicity occurs . Patients negative EGFR mutation result offer treatment per centre 's standard care .</brief_summary>
	<brief_title>A Study Assess Incidence EGFR Mutation Patients With Newly Diagnosed Locally Advanced Metastatic Non-Small Cell Lung Cancer UK , And Tarceva ( Erlotinib ) First-Line Therapy EGFR Mutation Positive Patients .</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Locally advanced metastatic ( stage IIIB/IV ) nonsmall cell lung cancer ( NSCLC ) ECOG performance status 03 Treatment phase : histologically confirm EGFR exon 19 deletion exon 21 mutation diagnostic phase study Adequate haematological , liver renal function Female patient must postmenopausal , surgically sterile , agree use barrier method contraception Male patient must surgically sterile agree use barrier method contraception Previous treatment NSCLC chemotherapy therapy EGFR , either antibody small molecule ( tyrosine kinase inhibitor ) Symptomatic cerebral metastasis Pregnant lactate woman Any concomitant anticancer therapy ( disease progression discontinuation Tarceva therapy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>